Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailMonte Carlo Simulations of Autorotative Dynamics of a Simple Tower Crane Model
Vanvinckenroye, Hélène ULg; Denoël, Vincent ULg

in Proceedings of the 14th International Conference on Wind Engineering (2015)

The increasing number of crane accidents recorded over the last years might be understood as a need for progress on crane modeling. The induced risk of self-excited vibrations has already been ... [more ▼]

The increasing number of crane accidents recorded over the last years might be understood as a need for progress on crane modeling. The induced risk of self-excited vibrations has already been investigated through numerous experiments. This work presents a simple numerical model of a crane in a turbulent wind field, in order to support the available experimental approaches. First, the problem is defined with the necessary assumptions of the model. Second, the equation of motion is developed and wind characteristics are detailed. This equation presents several specificities requiring dedicated resolution methods. In a first analysis, the crane model is simplified in order to approach the behavior of the parametric pendulum and enable a general comparison of both responses. Indeed, the parametric pendulum is a well-known problem that is already widely described in the literature. In a second step, the response of the crane is studied under a realistic stochastic wind load with the full model. [less ▲]

Detailed reference viewed: 57 (14 ULg)
Full Text
Peer Reviewed
See detailMonte Carlo simulations of the dose from imaging with GE eXplore 120 micro-CT using gate.
Bretin, Florian; Bahri, Mohamed Ali ULg; Luxen, André ULg et al

in Medical Physics (2015), 42(10), 5711-5719

Purpose: Small animals are increasingly used as translational models in preclinical imaging studies, during which the subjects can be exposed to large amounts of radiation. While the radiation levels are ... [more ▼]

Purpose: Small animals are increasingly used as translational models in preclinical imaging studies, during which the subjects can be exposed to large amounts of radiation. While the radiation levels are generally sublethal, studies have shown that low-level radiation can change physiological parameters in mice. In order to rule out any influence of radiation on the outcome of such experiments, or resulting deterministic effects in the subjects, the levels of radiation involved need to be addressed. The aim of this study was to investigate the radiation dose delivered by the GE eXplore 120 microCT non-invasively using Monte Carlo simulations in GATE and to compare results to previously obtained experimental values. Methods: Tungsten X-ray spectra were simulated at 70, 80, and 97 kVp using an analytical tool and their half-value layers were simulated for spectra validation against experimentally measured values of the physical X-ray tube. A Monte Carlo model of the microCT system was set up and four protocols that are regularly applied to live animal scanning were implemented. The computed tomography dose index (CTDI) inside a PMMA phantom was derived and multiple field of view acquisitions were simulated using the PMMA phantom, a representative mouse and rat. Results: Simulated half-value layers agreed with experimentally obtained results within a 7% error window. The CTDI ranged from 20 to 56 mGy and closely matched experimental values. Derived organ doses in mice reached 459 mGy in bones and up to 200 mGy in soft tissue organs using the highest energy protocol. Dose levels in rats were lower due to the increased mass of the animal compared to mice. The uncertainty of all dose simulations was below 14%. Conclusions: Monte Carlo simulations proved a valuable tool to investigate the 3D dose distribution in animals from microCT. Small animals, especially mice (due to their small volume), receive large amounts of radiation from the GE eXplore 120 microCT, which might alter physiological parameters in a longitudinal study setup. [less ▲]

Detailed reference viewed: 39 (3 ULg)
Full Text
Peer Reviewed
See detailMonte-Carlo Tree Search in Backgammon
Van Lishout, François ULg; Chaslot, Guillaume; Uiterwijk, Jos W.H.M.

(2007)

Monte-Carlo Tree Search is a new method which has been applied successfully to many games. However, it has never been tested on two-player perfect-information games with a chance factor. Backgam- mon is ... [more ▼]

Monte-Carlo Tree Search is a new method which has been applied successfully to many games. However, it has never been tested on two-player perfect-information games with a chance factor. Backgam- mon is the reference game of this category. Today’s best Backgammon programs are based on reinforcement learning and are stronger than the best human players. These programs have played millions of offline games to learn to evaluate a position. Our approach consists rather in playing online simulated games to learn how to play correctly in the current position. [less ▲]

Detailed reference viewed: 258 (7 ULg)
Full Text
Peer Reviewed
See detailMonte-Cristo chimiste et physicien des communications : du télégraphe optique au télégraphe électrique
Durand, Pascal ULg

in Cahiers Alexandre Dumas (2014), 41

The modernity of the optical telegraph scene in Le Comte de Monte-Cristo was rather outmoded in 1845. It can be nevertheless viewed as the index of a critical allegory of the technologies of communication ... [more ▼]

The modernity of the optical telegraph scene in Le Comte de Monte-Cristo was rather outmoded in 1845. It can be nevertheless viewed as the index of a critical allegory of the technologies of communication, including the electric telegraph. [less ▲]

Detailed reference viewed: 392 (117 ULg)
See detailMonteverdi letterato
Moreno, Paola ULg

Report (2011)

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailMonth-to-month variability of the general circulation fields in the western Mediterranean and the Gulf of Lions
Beckers, Jean-Marie ULg; Brasseur, P.

in Water Pollution Research (1993), 30

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailMonthly oral ibandronate is at least as effective as daily oral ibandronate in increasing hip BMD in postmenopausal osteoporosis : 1-year results from mobile
Cooper, C.; Stepan, J. J.; Lorenc, R. et al

in BONE (2005), 36(S2), 417

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailMonthly oral ibandronate is at least as effective as daily oral ibandronate: 1-year results from MOBILE
Reginster, Jean-Yves ULg; Cooper, Cyrus; Miller, P. D. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 81-82

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailMonthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
Stakkestad, Jacob A; Lakatos, Peter; Lorenc, Roman et al

in Clinical Rheumatology (2008), 27(8), 955-60

Oral ibandronate is the first bisphosphonate licensed for once-monthly treatment of postmenopausal osteoporosis. The 2-year Monthly Oral iBandronate In LadiEs (MOBILE) registration study assessed bone ... [more ▼]

Oral ibandronate is the first bisphosphonate licensed for once-monthly treatment of postmenopausal osteoporosis. The 2-year Monthly Oral iBandronate In LadiEs (MOBILE) registration study assessed bone mineral density (BMD) and markers of bone turnover and showed that monthly oral ibandronate was at least as effective and well tolerated as a 2.5-mg daily oral regimen. In this study, we report the first year of a long-term extension study to MOBILE and a post hoc analysis of patients receiving 3 years of continuous treatment with monthly ibandronate. Patients who completed MOBILE were eligible for the partially randomized, double-blind extension study and received 100 mg (n = 359) or 150 mg (n = 360) monthly oral ibandronate. A post hoc analysis included patients who received either 100 mg (n = 173) or 150 mg (n = 169) monthly ibandronate continuously throughout the original 2-year MOBILE study and during the first year of the extension study. After one additional year of treatment (total of 3 years), mean lumbar spine BMD increased a further 1.5 and 1.1% in the 150 and 100 mg arms, respectively, compared with 2-year data (original MOBILE study). Total hip BMD changed by 0.3 and -0.08%, respectively. In the post hoc analysis, 3-year increases in lumbar spine BMD were significant in patients receiving ibandronate 150 mg monthly (7.6%; p < 0.0001 vs. baseline) and 100 mg monthly (6.4%; p < 0.0001 vs. baseline). Both groups achieved significant increases in total hip BMD after 3 years compared with baseline (3.4%, 100 mg; 4.1%, 150 mg; p < 0.0001). Serum C-telopeptide of the alpha chain of type I collagen decreased significantly over 3 years' treatment (p < 0.001; all comparisons vs. baseline), remaining within the premenopausal range. Once-monthly oral ibandronate was well tolerated with a low incidence of clinical osteoporotic fractures and upper gastrointestinal events. In conclusion, 150-mg monthly oral ibandronate is an effective and well-tolerated long-term treatment for postmenopausal osteoporosis, with consistent improvement in BMD and bone turnover during 3 years' continuous treatment. [less ▲]

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailMonthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study
Reginster, Jean-Yves ULg; Wilson, K. M.; Dumont, Etienne et al

in Journal of Clinical Endocrinology and Metabolism (2005), 90(9), 5018-5024

Context: Ibandronate, a potent, nitrogen-containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly ... [more ▼]

Context: Ibandronate, a potent, nitrogen-containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly oral bisphosphonates through once-monthly oral dosing. Objective: The purpose of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of once-monthly oral ibandronate. Design: A randomized, 3-month, double-blind, placebo-controlled, phase I study (Monthly Oral Pilot Study) was conducted. Setting: The study was conducted at five clinical trial centers in the United Kingdom and Belgium. Patients or Other Participants: Subjects were postmenopausal women (age, 55 - 80 yr; >= 3 yr post menopause; n = 144). Intervention(s): Once-monthly oral ibandronate 50, 100, or 150 mg or placebo was used. After the first cycle, the 50-mg arm was split, with participants continuing on either 50 or 100 mg. Main Outcome Measure(s): Primary outcome measures were safety, serum and urinary C-telopeptide (CTX), and serum ibandronate AUC(0-infinity). Results: Once- monthly oral ibandronate was well tolerated, with a similar overall and upper gastrointestinal safety profile to placebo. Once- monthly ibandronate was also highly effective in decreasing bone turnover; substantial reductions from baseline in serum CTX (-56.7% and -40.7% in the 150- and 100- mg arms, respectively; P < 0.001 vs. placebo) and urinary CTX (-54.1% and -34.6%, respectively; P < 0.001 vs. placebo) were observed at d 91 (30 d after the final dose). Analysis of the area under the effect curve (d1 - 91) for change from baseline (percent x days) in serum CTX and urinary CTX indicated a dose- response relationship. The AUC(0-infinity) for ibandronate increased with dose but not in a dose- proportional manner. Conclusions: These findings indicate a potential role for once-monthly oral ibandronate in the treatment of postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailMonthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
Miller, Paul D.; McClung, Michael R.; Macovei, Liviu et al

in Journal of Bone and Mineral Research (2005), 20(8), 1315-1322

Introduction: Suboptimal adherence to daily and weekly oral bisphosphonates can potentially compromise therapeutic outcomes in postmenopausal osteoporosis. Although yet to be prospectively shown in ... [more ▼]

Introduction: Suboptimal adherence to daily and weekly oral bisphosphonates can potentially compromise therapeutic outcomes in postmenopausal osteoporosis. Although yet to be prospectively shown in osteoporosis, evidence from randomized clinical trials in several other chronic conditions shows that reducing dosing frequency enhances therapeutic adherence. Ibandronate is a new and potent bisphosphonate with antifracture efficacy proven for daily administration and also intermittent administration with a dose-free interval of > 2 months. This report presents comparative data on the efficacy and safety of monthly and daily oral ibandronate regimens. Materials and Methods: MOBILE is a 2-year, randomized, double-blind, phase III, noninferiority trial. A total of 1609 women with postmenopausal osteoporosis were assigned to one of four oral ibandronate regimens: 2.5 mg daily, 50 mg/50 mg monthly (single doses, consecutive days), 100 mg monthly, or 150 mg monthly. Results: After 1 year, lumbar spine BMD increased by 3.9%, 4.3%, 4.1%, and 4.9% in the 2.5, 50/50, 100, and 150 mg arms, respectively. All monthly regimens were proven noninferior, and the 150 mg regimen superior, to the daily regimen. All monthly regimens produced similar hip BMD gains, which were larger than those with the daily regimen. All regimens similarly decreased serum levels of C-telopeptide, a biochemical marker of bone resorption. Compared with the daily regimen, a significantly larger proportion of women receiving the 100 and 150 mg monthly regimens achieved predefined threshold levels for percent change from baseline in lumbar spine (6%) or total hip BMD (3%). All regimens were similarly well tolerated. Conclusions: Monthly ibandronate is at least as effective and well tolerated as the currently approved daily ibandronate regimen in postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 25 (8 ULg)
Full Text
See detailLe monticule frasnien de la carrière du Nord à Frasnes (Belgique): sédimentologie, stratigraphie séquentielle et coraux
Boulvain, Frédéric ULg; Coen-Aubert, M.

in Professional Paper Belgian Geological Survey (1998), 285

Detailed reference viewed: 75 (10 ULg)
Full Text
See detailLe monticule frasnien de la carrière Saint-Remy : faciès et genèse
Boulvain, Frédéric ULg

in Toussaint, Jacques (Ed.) Marbres jaspés de Saint-Remy et de la région de Rochefort (2012)

Detailed reference viewed: 34 (1 ULg)
Full Text
See detailMontrer des corps... libres
Englebert, Jérôme ULg

in Nollet, Lieven (Ed.) Condamné, pas coupable (2010)

Detailed reference viewed: 47 (9 ULg)
Full Text
See detailMontrer l’invisible. Les dieux et leurs statues dans la céramique grecque
Collard, Hélène ULg

in Borgeaud, Philippe; Fabiano, Doralice (Eds.) Perception et construction du divin dans l'Antiquité (2013)

Cette étude examine un groupe de vases particuliers, qui amènent une série de questions intéressantes sur le statut de l’image divine et sur les modes de représentation du divin en Grèce ancienne. Il ... [more ▼]

Cette étude examine un groupe de vases particuliers, qui amènent une série de questions intéressantes sur le statut de l’image divine et sur les modes de représentation du divin en Grèce ancienne. Il s’agit de documents attiques et italiotes sur lesquels une divinité est représentée à côté de sa propre statue. La question qui se pose d’emblée est celle du sens de ce type de figuration, qui « redouble » en quelque sorte la divinité. On tente de montrer ici que le « redoublement » n’est pas une simple redondance, car ces images mettent en scènes deux modes de présence différents. [less ▲]

Detailed reference viewed: 104 (9 ULg)
Full Text
See detailMontrer l'invisible. Rituel et présentification du divin dans l'imagerie attique
Collard, Hélène ULg

Book published by Presses Universitaires de Liège (2016)

Comment faire voir ce qui ne se voit pas ? Comment représenter la communication avec les dieux dans la figuration d’un rituel ? Ce sont de telles questions qu’ont dû affronter les peintres de vases ... [more ▼]

Comment faire voir ce qui ne se voit pas ? Comment représenter la communication avec les dieux dans la figuration d’un rituel ? Ce sont de telles questions qu’ont dû affronter les peintres de vases athéniens dans la mise en image des actes posés en l’honneur d’une pluralité d’entités divines. Afin de « présentifier l’invisible », ils ont ainsi développé diverses stratégies figuratives qu’il s’agit de saisir par le biais des séries d’images qui les mettent en œuvre. Les différentes formulations graphiques de la présence divine au rituel sont au cœur de ce livre qui scrute l’imagerie des vases attiques des VIe et Ve siècles avant notre ère afin de nourrir le questionnement sur la représentation et la perception du divin dans le polythéisme grec. [less ▲]

Detailed reference viewed: 41 (2 ULg)
Full Text
Peer Reviewed
See detailMontrer, calculer, explorer, analyser. Ce que l'informatique fait (faire) à l'analyse qualitative
Lejeune, Christophe ULg

in Recherches Qualitatives (2010), 9

Au delà de ses implications techniques, l'informatisation de l'analyse de texte soulève des questions de méthode. Après un recensement des motivations à recourir à des logiciels pour assister l'analyse de ... [more ▼]

Au delà de ses implications techniques, l'informatisation de l'analyse de texte soulève des questions de méthode. Après un recensement des motivations à recourir à des logiciels pour assister l'analyse de données textuelles, nous proposons une typologie distinguant cinq fonctionnalités proposées par ces outils : la lexicométrie, les concordances, les automates, les outils réflexifs et les dictionnaires. Chacune de ces fonctionnalités éclaire les textes d'une manière originale (et partielle). Rapportée à ses usages attestés, chacune de ces potentialités articule des présupposés épistémologiques spécifiques. En définitive, le choix d'un logiciel caractérise autant une démarche de recherche que l'inscription dans un paradigme. [less ▲]

Detailed reference viewed: 2099 (191 ULg)